Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program
Key Highlights
- ➤2026 revenue guidance cut to $3.09 billion from previous $3.18-$3.22 billion range
- ➤$500 million added to existing share repurchase authorization
- ➤Q3 net sales $763.7 million, down 0.7% year over year
- ➤GAAP diluted EPS $1.04, up 18.2% year over year
- ➤Enabling Technologies revenue grew 24%, with robot and navigation deployments up 73%
Expert Statements
Keith Pfeil, President and Chief Executive Officer of Globus Medical
“Third quarter revenue finished at $764 million, down slightly from the prior year quarter”
Keith Pfeil, President and Chief Executive Officer of Globus Medical
“U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter.”
Keith Pfeil, President and Chief Executive Officer of Globus Medical
“On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation.”
Keith Pfeil, President and Chief Executive Officer of Globus Medical
“Our Enabling Technologies strategy continued to make progress, delivering revenue growth of 24%, while simultaneously deploying 73% more robot and navigation units as compared to the prior year quarter, reflecting continued strong demand for our technology and execution against our capital deployment plan.”
Keith Pfeil, President and Chief Executive Officer of Globus Medical
“We remain focused on our long-term strategy of achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.”
Kyle Kline, Chief Financial Officer of Globus Medical
“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation.”
Kyle Kline, Chief Financial Officer of Globus Medical
“Our performance reflects disciplined execution across the business, which positions us to deliver sustained earnings growth, cash generation, and enhanced shareholder returns.”
Kyle Kline, Chief Financial Officer of Globus Medical
“To further this commitment, our Board has authorized a $500 million increase to our existing share repurchase program, which reflects confidence in our long-term growth profile and underlying earnings and cash generation prowess.”
AUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Results * Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of 0.5% on a constant currency basis. * Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an increase of 3.0%, as reported. * GAAP net income for the quarter was $141.2 million. * GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Non-GAAP diluted EPS was $1.23, an increase of 4.4%. * GAAP gross profit as a percentage of net sales was 66.7%, an increase of 2.5%. Non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%, an increase of 1.4%. “Third quarter revenue finished at $764 million, down slightly from the prior year quarter,” commented Keith Pfeil, President and Chief Executive Officer. “U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation. Our Enabling Technologies strategy continued to make progress, delivering revenue growth of 24%, while simultaneously deploying 73% more robot and navigation units as compared to the prior year quarter, reflecting continued strong demand for our technology and execution against our capital deployment plan. We remain focused on our long-term strategy of achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.”
Get started
Create a free account to read the full story.